Biotech Update


The biotech industry is poised for a breakout in 2017 after a disastrous 2016. Here’s what you need to know:

The Decline

2016 was a year marred by political pressure and uncertainty within the biotech industry. Headed by poster boy Martin Shkreli, the biotech industry took a bad fall after Shkreli, the CEO of Turing Pharmaceuticals, upped the price of a malaria medication 5000%. Eventually, Shkreli made his way to congress where even more bad publicity was heaped upon biotech as certain news outlets called Shkreli, “the most hated man in America”

With the Obama administration alleging that certain large biotech firms were involved in price fixing, the whole industry took a tumble. The NASDAQ Biotechnology Index took a hit of 19.6% in 2016. Evidently, there is such thing as bad publicity and the biotech industry felt the brunt of it. Teva Pharmaceutical Industries, a global leader in manufacturing and marketing generic drugs, saw their stock nosedive by 37.2% in 2016.

After the Martin Shkreli goes to congress fiasco, lawmakers on both sides of the aisle pushed hard to pressure these biotech companies to reduce drug prices. The proposed regulations saw investors flock to drop biotech stock.


2017 has been a rebirth for the biotech industry as it rises from the ashes of 2016. Already, the NASDAQ Biotechnology Index is up 9.4%. Investors have already forgotten about the drug scandals that scarred biotech last year.

The new Trump administration has made it clear that they will find ways to deregulate the industry, making it easier for these giant pharmaceutical companies to make a profit. These companies won’t be the subject of investigations from the Department of Justice as President Trump’s pro-business administration pushes through laws.

One of Trump’s proposed changes is to streamline the process that a drug company can get new drugs approved by the FDA. Only 22 new drugs were approved in 2016 amid all the controversy, the lowest total since 2010. You can expect much higher numbers under Trump.

Find the Game Changers

The future looks bright for the biotech industry. In 2015, 88% of all prescriptions were generic drug prescriptions, and that number looks to grow to around 92% by 2020. There is a lot of room to grow within this sector. How does one find the individual stocks that should see a rise in the coming years? You have to find the game changers.

This is what’s known in the industry as “disruption”. When a company finds a way to make your phone smaller, that’s disruption. A company that makes a more effective vaccine, that’s disruption within the biotech industry. A revolutionary idea or product that makes others before it obsolete.

Look for companies that are close to getting a product approved by the FDA. A company like Rigel Pharmaceuticals, Inc. has a new drug candidate that is close to being approved. The stock is low enough now that it will soar if this new drug for chronic ITP (immune thrombocytopenic purpura) is approved.

You can also look to the established players. As noted above, Teva Pharmaceuticals saw its stock plummet during some uneasy months in 2016. They lost a key drug patent, had a CEO resign and had to deal with the aforementioned price fixing scandal. This could be a chance to pick Teva up for a discount. Let’s not forget, this is still the world’s largest generic drug manufacturer.

Trending Up

Generally, the healthcare sector has trended upwards over the last 10 years, outperforming the overall U.S. economy.

biotech1*Both series indexed to 100 at January 2012

This graph shows the performance of the overall U.S. economy versus just the healthcare sector. Healthcare, in blue, clearly outpaces the S&P 500. There’s no reason to think 2017 will be different.



January 2, 2021 Update: We have just announced our BEST STOCK NEWSLETTER of 2020 AWARD!

CLICK HERE to find out which stock newsletter was up 78% in 2020 (and whose 2019 picks are now up 113%).

*** Our Award for BEST STOCK NEWSLETTER of 2020 ALERT ***

Updated January 2, 2021

At WallStreetSurvivor, we subscribe to dozens stock recommendation and advisory newsletters. There is ONE newsletter that is constantly outperforming all of the others--The Motley Fool Stock Advisor.

Five of their 2020 stock picks have doubled and the average return of all 24 of their stock picks for 2020 is up 78%!

We have been tracking ALL of the Motley Fool stock picks since January 2016. That's 5 years and 120 stock picks. As of Friday, January 1, 2021 the Motley Fool's January stock pick (TSLA) is up 720%, their March pick (ZM) is up 172%, their April pick of SHOP is up 226% and their June pick CRWD is up 120%; and another two have more than doubled. In addition, 10 of their 2019, 12 of their 2018, 11 of their 2017, 15 of their 2016. Most impressively, over the last 5 years that we have been tracking every recommendation, their average stock pick is up 209%--tht means over the last 5 years their stock picks, on average, have TRIPLED!

Now no one can guarantee that their next picks will be as strong, but our 5 years of experience has been super-profitable. The important thing about the Fool stock picks is you have to buy them the day they are recommended because they usually pop 5-10% in the first 72 hours after the release their recommendation. You sure don’t want to risk missing out on their next pick.

Normally the Fool service is priced at $199 per year but they are currently offering a NEW SUBSCRIBER DISCOUNT that allows you to get theiir next 24 stock picks for just $99/year. HERE is the LINK to visit their New Subscriber Discount page.

CLICK HERE to get access to all The Motley Fool’s Stock Picks and their next 12 months of picks for just $99 per Year! 



Robinhood was the first brokerage site to NOT charge commissions when they opened in 2013. They just past 10,000,000 accounts and to celebrate they are offering up to $1,000 in free stock when you open a new account.

Here’s the details: You must click on a special promo link to open your new Robinhood account. Then when you fund your account with at least $10, you will receive one stock valued between $5 and $500. Then, you will get a link to share with your friends. Every time one of your friends opens an account, you will receive another free stock valued between $5 and $500. Click here to learn more about this Special Robinhood offer.

Claim your free stock NOW (before it’s too late)

2 responses to “Biotech Update”

  1. Uneeb Ahmad says:

    Just checking

  2. prosper says:

    Nice Post.Graeat.Technology is rapidly changing